Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆

@article{Schally1999LuteinizingHH,
  title={Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆},
  author={Andrew V. Schally},
  journal={Peptides},
  year={1999},
  volume={20},
  pages={1247-1262}
}
  • A. Schally
  • Published 1 October 1999
  • Medicine, Biology
  • Peptides
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
  • J. Engel, A. Schally
  • Medicine, Biology
    Nature Clinical Practice Endocrinology &Metabolism
  • 2007
TLDR
Analogs of LHRH are now a well-established means of treating sex-steroid-dependent, benign and malignant disorders, and have been successfully used to treat prostate cancer and benign prostatic hypertrophy.
Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer
TLDR
Experimental studies and early clinical trials with targeted cytotoxic L HRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are described and reviewed.
Agonists of luteinizing hormone-releasing hormone in prostate cancer
TLDR
Degarelix, a highly clinically effective third-generation L HRH antagonist, is currently available in most countries for therapy of advanced PCa and offers attractive alternatives to LHRH agonists for treatment ofAdvanced PCa.
The LHRH antagonist cetrorelix: a review.
TLDR
The concept that a complete suppression of sex-steroids may not be necessary in indications such as uterine fibroma, endometriosis and benign prostatic hyperplasia represents a promising novel perspective for treatment of these diseases.
Hypothalamic Hormones and Cancer
TLDR
Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases.
Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152
TLDR
Intravenous administration of AN-152 is far less toxic and inhibits the growth of LHRH receptor-positive tumors better than equimolar doses of the cytotoxic agent doxorubicin.
Aplicaciones en ginecología de los antagonistas de LH-RH
The modifications to the native LH-RH produced the appearance of the analogs: agonist whose applications in the area of reproductive medicine has been shown to be safe and effective in the treatment
...
...

References

SHOWING 1-10 OF 181 REFERENCES
LH-RH analogues: I. Their impact on reproductive medicine.
  • A. Schally
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 1999
TLDR
Modern LH-RH antagonists such as cetrorelix may prove superior to the agonists in COS-ART and also in the treatment of BPH, but additional studies in these and other areas are needed.
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.
TLDR
The premature LH surge, the main cause of cancellation during induction of superovulation in assisted reproduction technology (ART) programmes, can be abolished by short term application of an LHRH antagonist associated with a reduced human menopausal gonadotrophin (HMG) requirement for ovarian stimulation.
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
TLDR
Experimental data and several pilot clinical trials suggest that in epithelial ovarian cancer and sex-cord-stromal tumours of the ovary, LHRH agonists might have antitumour activity through the suppression of gonadotrophin secretion (selective medical hypophysectomy).
Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
TLDR
The results clearly suggest that the antiproliferative effect of LHRH agonists on LNCaP cells may be mediated by specific receptors.
Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists.
TLDR
A number of highly potent agonistic analogs of GnRH have now been described and are in various stages of clinical evaluation, with increases in potency over the native hormone related to increased binding affinity and consequent retardation in dissociation rate from the receptors.
Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
TLDR
The data seem to indicate that an autocrine/paracrine L HRH (or LHRH-like) loop is present in androgen-independent prostate cancer cells, and may participate in the regulation of tumor cell growth.
Gonadotropin-releasing hormone and its analogs.
TLDR
The physiologic and pharmacologic principles underlying the advances produced by these agents, the mechanism of action of GnRH and its analogues at the cellular level, and the individual therapeutic applications to which these analogues have been applied are examined.
Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas.
TLDR
Reversible temporary medical oophorectomy using long-acting agonist analogs of LH-RH was tried in three infertile patients suffering from large endometriomas of the ovary, with evident improvement of abdominal pain, dysmenorrhea, and dyspareunia and Administration of D-Trp6-LH- RH was more effective than D-Ala6- LH-RH PA in most of the parameters tested.
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
TLDR
The binding of luteinizing hormone-releasing hormone analogues to the human mammary tumor cell line MCF-7 and their effect on the cell proliferation was studied to elucidate their direct action on estrogen-dependent mammary tumors, and it was found that SB-75 inhibited the stimulation of growth by buse Relin, but buserelin did not prevent the inhibition by the antagonist of the estrogen- dependent growth.
...
...